Martine J Hollestelle

Summary

Affiliation: University Medical Center Utrecht
Country: The Netherlands

Publications

  1. ncbi Tolerance to factor VIII in a transgenic mouse expressing human factor VIII cDNA carrying an Arg(593) to Cys substitution
    Wendy S Bril
    Department of Plasma Proteins, Sanquin Research at CLB, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands
    Thromb Haemost 95:341-7. 2006
  2. ncbi Characterization of gastrin-cholecystokinin 2 receptor interaction in relation to c-fos induction
    Martine J Hollestelle
    Department of Metabolic and Endocrine Diseases, University Medical Center Utrecht, Lundlaan 6, Utrecht, The Netherlands
    Endocr Relat Cancer 15:301-9. 2008
  3. ncbi Decreased active von Willebrand factor level owing to shear stress in aortic stenosis patients
    M J Hollestelle
    Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    J Thromb Haemost 9:953-8. 2011
  4. ncbi Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity
    Martine J Hollestelle
    Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    PLoS ONE 6:e24216. 2011
  5. ncbi Designing antibodies for the inhibition of gastrin activity in tumoral cell lines
    Rodrigo Barderas
    Protein Technology Unit, Biotechnology Program, Spanish National Cancer Research Center CNIO, Madrid, Spain
    Int J Cancer 122:2351-9. 2008
  6. ncbi von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation
    Martine J Hollestelle
    Sanquin, Amsterdam, The Netherlands
    Br J Haematol 133:562-9. 2006

Collaborators

  • P J Lenting
  • Peter Timmerman
  • Philip G de Groot
  • Tom Sprong
  • B J Bouma
  • Rodrigo Barderas
  • Wendy S Bril
  • Jo W M Höppener
  • Danièle Altschuh
  • Rob Meloen
  • Jorge L Martinez-Torrecuadrada
  • Susana Shochat
  • Jose Ignacio Casal
  • Birgit M Reipert
  • Karin Fijnvandraat
  • Christina Hausl
  • Koen Mertens
  • Rafi U Ahmad
  • Rene A W van Lier
  • Hans Peter Schwarz
  • Jan Voorberg
  • Marleen G Zuurveld
  • Pauline M W van Helden
  • Pieter H Reitsma

Detail Information

Publications6

  1. ncbi Tolerance to factor VIII in a transgenic mouse expressing human factor VIII cDNA carrying an Arg(593) to Cys substitution
    Wendy S Bril
    Department of Plasma Proteins, Sanquin Research at CLB, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands
    Thromb Haemost 95:341-7. 2006
    ..These results indicate that huFVIII-R593C/E-16KO mice are tolerant to intravenously administered factor VIII. It is anticipated that this model may prove useful for studying immune responses in the context of factor VIII gene therapy...
  2. ncbi Characterization of gastrin-cholecystokinin 2 receptor interaction in relation to c-fos induction
    Martine J Hollestelle
    Department of Metabolic and Endocrine Diseases, University Medical Center Utrecht, Lundlaan 6, Utrecht, The Netherlands
    Endocr Relat Cancer 15:301-9. 2008
    ....
  3. ncbi Decreased active von Willebrand factor level owing to shear stress in aortic stenosis patients
    M J Hollestelle
    Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    J Thromb Haemost 9:953-8. 2011
    ..To elucidate a possible role of circulating preactivated von Willebrand factor (VWF), we determined the level of VWF in its active, platelet-binding conformation in plasma of patients with aortic stenosis...
  4. ncbi Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity
    Martine J Hollestelle
    Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    PLoS ONE 6:e24216. 2011
    ....
  5. ncbi Designing antibodies for the inhibition of gastrin activity in tumoral cell lines
    Rodrigo Barderas
    Protein Technology Unit, Biotechnology Program, Spanish National Cancer Research Center CNIO, Madrid, Spain
    Int J Cancer 122:2351-9. 2008
    ..These findings should contribute to a more rational design of antibody-based antigastrin therapies in cancer, including passive administration of human antibodies with blocking activity...
  6. ncbi von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation
    Martine J Hollestelle
    Sanquin, Amsterdam, The Netherlands
    Br J Haematol 133:562-9. 2006
    ..These novel findings potentially implicate acute, regulated exocytosis of endothelial cell Weibel-Palade bodies in the pathogenesis of Plasmodium falciparum malaria...